Side-by-side · Research reference

SurvodutidevsTeriparatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED25/54 cited

BFDA-ApprovedHUMAN-REVIEWED10/62 cited

Survodutide

GLP-1/Glucagon Dual Agonist · Phase 3

Once weeklyFrequency

Phase 3Development stageRubino 2026

GLP-1/GCGRDual targetZimmermann 2026

SQ · Once Weekly

Teriparatide

PTH (1-34) Fragment · FDA-Approved

20 mcgDaily dose

12-18 moAnabolic windowFerrari 2026

SQRoute

SQ · Thigh/Abdomen · Once Daily

01Mechanism of Action

Parameter

Survodutide

Teriparatide

Primary target

GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026 Zimmermann 2026

Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026

Pathway

Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026 Long 2026

PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity

Downstream effect

Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026 Yathindra 2026

Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites

Feedback intact?

—

Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption

Origin

—

Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH

Antibody development

—

02Dosage Protocols

Parameter

Survodutide

Teriparatide

Standard dose

Not yet disclosed (Phase 3 ongoing)

SYNCHRONIZE Phase 3 program underway.Rubino 2026

—

Frequency

Once weekly

Once daily

Intermittent administration preserves anabolic effect.

Route

SubcutaneousYathindra 2026

Subcutaneous (thigh or abdomen)

Evidence basis

Phase 2 RCT (obesity) · Phase 3 ongoing

RCT / FDA-approved

Phase 2 findings

Significant weight loss and metabolic marker improvementYathindra 2026

—

MASH indication

Under investigation for MASH-cirrhosisPatil 2026 Andonie 2026

—

Standard dose (osteoporosis)

—

20 mcg / day

FDA-approved regimen for severe osteoporosis.

Maximum duration

—

24 months lifetime

Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.

Hypoparathyroidism dose

—

20 mcg / day

Used off-label for chronic hypoparathyroidism.

Pelvic fragility fractures

—

20 mcg / day × 8-12 weeks

Accelerates fracture healing; reduces time to union.Crooks 2026

Timing

—

Morning or evening (flexible)

Storage

—

Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use

Pharmacogenetics

—

ALDH2 polymorphisms may influence BMD responseObara 2026

ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026

03Metabolic / Fat Loss Evidence

Parameter

Survodutide

Teriparatide

Primary fat target

Total body weight, visceral adipose tissue

—

Weight loss mechanism

Dual action: decreased energy intake + increased energy expenditureZimmermann 2026

—

Phase 2 efficacy

Significant weight loss demonstrated

Specific percentage not disclosed in abstracts.

—

Metabolic markers

Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026 Abulehia 2026 Andonie 2026

—

MRI-PDFF reduction

Hepatic fat reduction demonstrated in MASH trialsAndonie 2026

—

Network meta-analysis

Favorable efficacy profile vs other glucagon receptor agonists

—

Hepatic requirement

Hepatic GCGR required for maximal weight loss and metabolic effectsLong 2026

—

Energy expenditure

Increased energy expenditure contributes to weight lossZimmermann 2026

—

Comparative efficacy

Network meta-analysis shows competitive efficacy in GRA class

—

Fat loss application

—

None — teriparatide is a bone anabolic agent without direct lipolytic activity

04Side Effects & Safety

Parameter

Survodutide

Teriparatide

GI symptoms

Diarrhea, nausea, fatigue — class effect of GLP-1 agonists

—

Safety profile

Network meta-analysis: comparable safety to other GRAs

—

Serious adverse events

Monitored in Phase 2/3; no unique safety signals reported

Detailed SAE data pending Phase 3 completion.

—

Injection site reactions

Expected with subcutaneous administration

—

Glucagon-related effects

Potential for tachycardia, increased blood pressure — theoretical glucagon effect

—

Hypercalcemia

—

Transient serum calcium elevation 4-6 hours post-injection

Monitor serum calcium; usually asymptomatic.

Orthostatic hypotension

—

Dizziness, lightheadedness within hours of injection

Nausea

—

Common, usually mild and transient

Leg cramps / Arthralgia

—

Musculoskeletal pain reported in clinical trials

Hypercalciuria

—

Increased urinary calcium excretion; monitor for nephrolithiasis risk

Osteosarcoma (black box warning)

—

Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation

Injection site reaction

—

Erythema, bruising, pain (uncommon)

Absolute Contraindications

Survodutide

·Personal or family history of medullary thyroid carcinoma (class effect)
·Multiple endocrine neoplasia syndrome type 2

Teriparatide

·Paget's disease of bone (increased baseline osteosarcoma risk)
·Unexplained elevated alkaline phosphatase
·Prior skeletal radiation therapy
·Skeletal malignancies or bone metastases
·Hypercalcemic disorders (primary hyperparathyroidism)
·Pregnancy / lactation

Relative Contraindications

Survodutide

·Severe GI disease (inflammatory bowel disease, gastroparesis)
·History of pancreatitis
·Cardiovascular disease (monitor closely for glucagon effects)

Teriparatide

·Active or recent nephrolithiasis
·Severe renal impairment (CKD G4-G5)
·Hypercalciuria without adequate monitoring

05Administration Protocol

Parameter

Survodutide

Teriparatide

1. Reconstitution

Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.

Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.

2. Injection site

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.

Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.

3. Timing

Once weekly, same day each week. Can be administered at any time of day, with or without meals.

Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.

4. Storage

Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.

Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.

5. Needle

Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.

Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.

6. Calcium and vitamin D supplementation

—

Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.